M a n u s c r i p t 4 | P a g e CONCLUSIONS-Small differences observed between IFCC-calibrated and NGSP certified methods across a wide HbA 1c range were confirmed by quality control and external quality assurance. As these offsets affect estimates of diabetes prevalence, the analyser (and calibrator) employed should be considered when evaluating diagnostic data.
M a n u s c r i p t
| P a g e
HbA 1c is important for the management of diabetes [1, 2] with its relationship to complications described by the Diabetes Control and Complications Trial (DCCT) and United Kingdom
Prospective Diabetes Study (UKPDS). In both clinical trials ion exchange high performance liquid chromatography (IE HPLC) was employed for reporting HbA 1c using Bio-Rad analysers [3] . More recently, HbA 1c has been recommended by the ADA [4] , WHO [5] and IDF [6] for the diagnosis of diabetes with a level of ≥6.5% (48 mmol/mol) selected as the cut-point because of its relationship to diabetic retinopathy in epidemiological studies [7, 8] .
HbA 1c is an attractive alternative to glucose being more stable after collection of blood, not as readily affected by short-term variations in glycaemia and not requiring fasting or time consuming procedures e.g. oral glucose tolerance testing (OGTT) [9] . It is easily measured in laboratories and at point of care (POCT) using a variety of techniques including IE HPLC, immunochemistry or boronate affinity chromatography [10] . Precise International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) calibrated methods are recommended in current guidelines [4] [5] [6] following the introduction of the IFCC reference method for HbA 1c [11] involving mass spectrometry and capillary electrophoresis which has been used to anchor calibration of routine methods since 2003.
Rather than a single HbA 1c cut-point for diagnosis some guidance from Germany [12] and the US [13] recommends using ranges e.g. ≥7.5% (58 mmol/mol) for ruling in diabetes and ≤5.5%
(37 mmol/mol) for ruling diabetes out with subsequent glucose testing for individuals who fall between 5.5% (37 mmol/mol) and 7.5% (58 mmol/mol) [14, 15] . Knowledge of any off-sets between field methods and IFCC HbA 1c values is important when cut-points are being used for the diagnosis of diabetes and narrow ranges for pre-diabetes.
A c c e p t e d M a n u s c r i p t 6 | P a g e As a result of this notification, 45 EDTA blood samples and IQC samples were measured on the laboratory Tosoh G8 IE HPLC analyser with the calibrator in use at the time i.e. Lot ZS2002 and also after the introduction of the revised calibrator Lot ZS3001.
QC
IQCs recommended by manufacturers were used with additional materials provided for samples processed in batch-mode.
Sample Collection and Storage
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Data sets for patients undergoing OGTT for diagnostic purposes with concurrent HbA 1c [15] were examined to assess the effect of any offset between routine HbA 1c assays and the IFCC SRM using probability density function graphs produced for these data sets and also for those obtained in this paper for patients referred to a university hospital for treatment of diabetes, M a n u s c r i p t
This study is limited because only a few analysers were involved with particular batches of assay consumables and calibrators. In addition, some samples were measured at the end of the study after storage at -70 o C. However, the results are in line with manufacturers' expectations and confirmed in internal quality control and national external quality assurance schemes e.g.
United Kingdom National External Quality Assessment Service (UK NEQAS) and CAP. (70 mmol/mol) on the Cobas c502 [23] were apparent on the scattergram.
These differences between IFCC-calibrated methods are in line with some attributed to populations in research studies without due consideration of the analyser employed for HbA 1c measurement [24] [25] [26] [27] [28] . In our previously published paper relating OGTT data to concurrent HbA 1c in the UK and Australia, it was unclear whether the differences in HbA 1c ranges quoted were related to the population, sampling or analysers [15, 25] . In Birmingham, HbA 1c was measured using the Tosoh G8 situated in the diabetes centre (as described in this paper) and in Australia using a Bio-Rad Variant II analyser -analysers with similarly high biases versus the IFCC SRM as observed in this study. Inspection of the HbA 1c distribution in these two populations in Figure 2 shows how the differences between results from routine IFCCcalibrated methods would impact on the number of patients being diagnosed with diabetes [29] . In conclusion: currently there is some debate about the particular requirements for the performance of IFCC-calibrated and NGSP certified HbA 1c assays for diagnostic purposes in addition to the treatment of patients with diabetes. Although using HbA 1c for diagnosis has been subject to systematic review [30] following much debate about its relationship to OGTT [31, 32] A c c e p t e d M a n u s c r i p t
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Figure 1a
Scatterplot with linear regression lines for HbA 1c measured by different IFCC-calibrated field methods and IFCC SRM, n=128.
Figure 1b
Difference plots for HbA 1c measured by IFCC-calibrated field methods versus IFCC SRM, n=128.
Colours of symbols as per Figure 1a , -zero line, ---mean difference & …. 1.96 SD
Figure 1c
Difference plot as above for Tosoh G8 IE HPLC analyser post recalibration (ZS3001) by manufacturer in September/October 2013 versus calibrator (ZS2002) with a bias equivalent to those calibrators used in the GFH Study, n=45.
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